Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.

Mateen S, Raina K, Jain AK, Agarwal C, Chan D, Agarwal R.

Epigenetics. 2012 Oct;7(10):1161-72. doi: 10.4161/epi.22070. Epub 2012 Sep 10.

2.
3.

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.

Takashina T, Kinoshita I, Kikuchi J, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Nishimura M, Dosaka-Akita H.

Cancer Sci. 2016 Jul;107(7):955-62. doi: 10.1111/cas.12957. Epub 2016 Jun 13.

4.

Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression.

Tseng TH, Chien MH, Lin WL, Wen YC, Chow JM, Chen CK, Kuo TC, Lee WJ.

Environ Toxicol. 2017 Feb;32(2):434-444. doi: 10.1002/tox.22247. Epub 2016 Feb 12.

PMID:
26872304
5.

SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.

Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP.

Oncol Rep. 2006 Jan;15(1):187-91.

PMID:
16328054
6.

Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis.

Habold C, Poehlmann A, Bajbouj K, Hartig R, Korkmaz KS, Roessner A, Schneider-Stock R.

J Cell Mol Med. 2008 Apr;12(2):607-21. doi: 10.1111/j.1582-4934.2007.00136.x. Erratum in: J Cell Mol Med. 2008 Aug;12(4):1421.

7.

Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.

Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F.

PLoS One. 2013;8(3):e58267. doi: 10.1371/journal.pone.0058267. Epub 2013 Mar 4.

8.

12-O-Tetradecanoyl phorbol-13-acetate (TPA)-induced growth arrest is increased by silibinin by the down-regulation of cyclin B1 and cdc2 and the up-regulation of p21 expression in MDA-MB231 human breast cancer cells.

Kim S, Lee HS, Lee SK, Kim SH, Hur SM, Kim JS, Kim JH, Choe JH, Shin I, Yang JH, Lee JE, Nam SJ.

Phytomedicine. 2010 Dec 1;17(14):1127-32. doi: 10.1016/j.phymed.2010.03.013.

PMID:
20554189
9.

Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.

Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A.

Cancer Sci. 2010 Jun;101(6):1424-30. doi: 10.1111/j.1349-7006.2010.01559.x. Epub 2010 Mar 10.

10.

P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells.

Bajbouj K, Mawrin C, Hartig R, Schulze-Luehrmann J, Wilisch-Neumann A, Roessner A, Schneider-Stock R.

J Neurooncol. 2012 May;107(3):503-16. doi: 10.1007/s11060-011-0791-2. Epub 2012 Jan 20.

PMID:
22270849
11.

Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells.

Feng W, Cai D, Zhang B, Lou G, Zou X.

Biomed Pharmacother. 2015 Aug;74:257-64. doi: 10.1016/j.biopha.2015.08.017. Epub 2015 Aug 28.

PMID:
26349994
12.

P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.

Hsieh YJ, Hwu L, Chen YC, Ke CC, Chen FD, Wang HE, Lin KP, Yeh HH, Chang CW, Liu RS.

J Nucl Med. 2014 Apr;55(4):678-85. doi: 10.2967/jnumed.113.126573. Epub 2014 Mar 17.

13.

The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.

Chen S, Zhao Y, Gou WF, Zhao S, Takano Y, Zheng HC.

PLoS One. 2013 Nov 13;8(11):e79781. doi: 10.1371/journal.pone.0079781. eCollection 2013.

14.

Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.

Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M, Lassmann S.

Epigenetics. 2015;10(5):431-45. doi: 10.1080/15592294.2015.1039216.

15.

Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.

Yang H, Xu W, Li Y, Lan P, Zhang J, Zhang Y, Zhang C.

Anticancer Drugs. 2014 Aug;25(7):767-77. doi: 10.1097/CAD.0000000000000101.

PMID:
24686006
16.

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Richon VM, Sandhoff TW, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9.

17.
18.

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.

Gui CY, Ngo L, Xu WS, Richon VM, Marks PA.

Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6. Epub 2004 Jan 20.

19.

A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.

Hwang JJ, Kim YS, Kim MJ, Jang S, Lee JH, Choi J, Ro S, Hyun YL, Lee JS, Kim CS.

Anticancer Drugs. 2009 Oct;20(9):815-21. doi: 10.1097/CAD.0b013e3283300a0f.

PMID:
19644355
20.

Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.

Bao L, Diao H, Dong N, Su X, Wang B, Mo Q, Yu H, Wang X, Chen C.

Cell Biol Toxicol. 2016 Dec;32(6):469-482. Epub 2016 Jul 16.

Supplemental Content

Support Center